Further Weakness as COFCO Biotechnology (SZSE:000930) Drops 5.3% This Week, Taking Three-year Losses to 41%
Further Weakness as COFCO Biotechnology (SZSE:000930) Drops 5.3% This Week, Taking Three-year Losses to 41%
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term COFCO Biotechnology Co., Ltd. (SZSE:000930) shareholders have had that experience, with the share price dropping 47% in three years, versus a market decline of about 31%. And over the last year the share price fell 32%, so we doubt many shareholders are delighted. Furthermore, it's down 24% in about a quarter. That's not much fun for holders. However, one could argue that the price has been influenced by the general market, which is down 13% in the same timeframe.
作爲股東,值得努力確保您的整體投資組合超過市場平均水平。但選股的風險在於您可能會買入表現不佳的公司。我們遺憾地報告說,長揸中糧科技股份有限公司(SZSE:000930)的股東們有過這樣的經歷,股價在三年內下跌了47%,而市場下跌約31%。而在過去一年裏,股價下跌了32%,因此我們懷疑很多股東都不會感到高興。此外,大約一個季度以來下跌了24%,對持有者來說並不太有趣。然而,有人可能會認爲股價受到了總體市場的影響,該市場在同一時間段內下跌了13%。
After losing 5.3% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.
在過去的一週中,股價下跌了5.3%,值得調查公司的基本面,以了解我們可以從過去的表現中得出什麼結論。
In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
禾倫·巴菲特在他的論文《格雷厄姆-道德斯維爾的超級投資者》中描述了股票價格並不總是合理地反映企業的價值。通過比較每股收益(EPS)和股價隨時間變化的變化,我們可以了解到投資者對某家公司的態度如何隨時間而變化。
COFCO Biotechnology saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.
中糧科技在過去三年中股價下跌,其每股收益也下降,降至虧損。由於公司陷入虧損地位,很難將每股收益的變化與股價變化進行比較。然而,我們可以說,我們預計在這種情況下股價會下跌。
You can see how EPS has changed over time in the image below (click on the chart to see the exact values).
您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。
It might be well worthwhile taking a look at our free report on COFCO Biotechnology's earnings, revenue and cash flow.
看看我們關於中糧科技收益、營業收入和現金流的免費報告可能是非常值得的。
What About The Total Shareholder Return (TSR)?
那麼,股東總回報(TSR)呢?
We'd be remiss not to mention the difference between COFCO Biotechnology's total shareholder return (TSR) and its share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. COFCO Biotechnology's TSR of was a loss of 41% for the 3 years. That wasn't as bad as its share price return, because it has paid dividends.
我們不得不提到中糧科技的總股東回報(TSR)與股價回報之間的差異。 TSR是一種回報率計算,考慮了現金股利的價值(假設任何股息收入都是再投資的)以及任何折價增資和分拆的計算值。 中糧科技的TSR在3年中虧損了41%。這並不像股價回報那樣糟糕,因爲它已支付股息。
A Different Perspective
不同的觀點
We regret to report that COFCO Biotechnology shareholders are down 32% for the year. Unfortunately, that's worse than the broader market decline of 16%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 4% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. You could get a better understanding of COFCO Biotechnology's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.
很遺憾地通報,中糧科技股東的年度回報率下降了32%。不幸的是,這比更廣泛的市場下跌16%還要糟糕。儘管如此,在下跌的市場中,一些股票被拋售是不可避免的。關鍵是要關注基本發展情況。遺憾的是,去年的表現結束了一段糟糕的時期,股東們在過去五年中面臨着每年4%的總損失。我們知道羅斯柴爾德男爵曾說過投資者應該「在大街上到處是鮮血時買入」,但我們警告投資者首先要確信自己正在購買一個高質量的企業。通過查看這個更詳細的歷史圖表,您可以更好地了解中糧科技的增長情況。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。